-
-
-
-
-
-
-
Bristol-Myers Squibb's (BMY) Abecma Approved in EU
-
-
-
-
-
-
-
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
-
-
-
-
-
-
-
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
-
-
-
-
-
-
-
Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results
-
-
-
-
-
-
-
Bristol Myers CEO sees mid-decade transition, late decade growth
-
-
-
-
-
-
-
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Ma
-
-
-
-
-
-
-
Bristol-Myers Squibb (BMY) Reports Eight-Year Data for Opdivo Plus Yervoy Continued to Demonstrate Longest Survival Benefit vs. Sunitinib
-
968,301 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All